CA Patent

CA3279332A1 — DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF

Assigned to Hangzhou Tianlong Pharmaceutical Co Ltd · Expires 2026-03-01 · 0y expired

What this patent protects

Patent listed against inclisiran-sodium.

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: CA3279332A1
Jurisdiction: CA
Classification: —
Expires: 2026-03-01
Drug substance claim: No
Drug product claim: No
Assignee: Hangzhou Tianlong Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.